These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Frassetto L; Baluom M; Jacobsen W; Christians U; Roland ME; Stock PG; Carlson L; Benet LZ Transplantation; 2005 Jul; 80(1):13-7. PubMed ID: 16003227 [TBL] [Abstract][Full Text] [Related]
64. Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations. Grevel J; Napoli KL; Welsh MS; Atkinson NE; Kahan BD Pharm Res; 1991 Feb; 8(2):278-81. PubMed ID: 2023881 [TBL] [Abstract][Full Text] [Related]
65. The effect of oral metoclopramide on the absorption of cyclosporine. Wadhwa NK; Schroeder TJ; O'Flaherty E; Pesce AJ; Myre SA; First MR Transplantation; 1987 Feb; 43(2):211-3. PubMed ID: 3544377 [TBL] [Abstract][Full Text] [Related]
66. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group. Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL Transplantation; 1996 Mar; 61(6):968-70. PubMed ID: 8623168 [TBL] [Abstract][Full Text] [Related]
67. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Min DI; Perry PJ; Chen HY; Hunsicker LG Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147 [TBL] [Abstract][Full Text] [Related]
68. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Blohmé I; Idström JP; Andersson T Br J Clin Pharmacol; 1993 Feb; 35(2):156-60. PubMed ID: 8443034 [TBL] [Abstract][Full Text] [Related]
69. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study. Zhang Y; Zhang XD; Wang Y Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829 [TBL] [Abstract][Full Text] [Related]
70. Influence of oral felodipine on serum cyclosporine concentrations. Cohen DJ; Teng SN; Appel GB Clin Transplant; 1994 Dec; 8(6):541-5. PubMed ID: 7865916 [TBL] [Abstract][Full Text] [Related]
71. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients. Schroeder TJ; Helling T; McKenna RM; Rush D; Jeffrey JR; Brewer B; Martin LA; Traylor D; Fisher RA; First MR Transplantation; 1992 Jan; 53(1):34-40. PubMed ID: 1733082 [TBL] [Abstract][Full Text] [Related]
72. Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. Cooney GF; Mochon M; Kaiser B; Dunn SP; Goldsmith B Pharmacotherapy; 1995; 15(3):353-6. PubMed ID: 7667170 [TBL] [Abstract][Full Text] [Related]
73. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Rotstein C; Bow EJ; Laverdiere M; Ioannou S; Carr D; Moghaddam N Clin Infect Dis; 1999 Feb; 28(2):331-40. PubMed ID: 10064252 [TBL] [Abstract][Full Text] [Related]
74. Safety of low-dose cyclosporine therapy before transplantation in kidney allograft recipients. Khosroshahi HT; Badrogli N; Jahannavard N; Oskuii R; Bahluli A; Azar SA; Ardalan M Transplant Proc; 2009 Sep; 41(7):2757-60. PubMed ID: 19765427 [TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. Henny FC; Kleinbloesem CH; Moolenaar AJ; Paul LC; Breimer DD; van Es LA Transplantation; 1985 Sep; 40(3):261-5. PubMed ID: 3898491 [TBL] [Abstract][Full Text] [Related]